Summit Therapeutics Inc. (SMMT) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 233 institutional investors hold a position in Summit Therapeutics Inc. (NASDAQ:SMMT).

• Summit Therapeutics saw its institutional ownership percentage rose to 14.1% in September 2025 from 13.6% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 4.52%, with a year-over-year an increase of 39.52% in the count of filers.
• Among the 233 institutional holders of Summit Therapeutics, 117 added to their stakes while 81 trimmed their positions and 35 held steady.
• The total number of shares held by institutions in Summit Therapeutics increased to 104.99Mn as of September 2025, a net change of up by 4.54Mn shares quarter on quarter, and up 18.31Mn shares year over year.
• With 33.72Mn shares, BAKER BROS. ADVISORS LP commands the largest institutional position in Summit Therapeutics as of September 30, 2025, equating to 4.54% of the company.
• Among the most significant buyers of Summit Therapeutics during September 2025 were VANGUARD GROUP INC (2.71Mn), STATE STREET CORP (2.34Mn), MORGAN STANLEY (1.28Mn), NOMURA HOLDINGS INC (1.00Mn), PRICE T ROWE ASSOCIATES INC /MD/ (633.67K).
• Leading sellers of Summit Therapeutics stock in September 2025 included BALYASNY ASSET MANAGEMENT L.P. (1.51Mn), UBS Group AG (815.17K), CITADEL ADVISORS LLC (796.03K), Caption Management, LLC (697.89K), Squarepoint Ops LLC (566.40K).
• The top 10 institutional holders of Summit Therapeutics for the quarter ending September 2025 included BAKER BROS. ADVISORS LP (33.72Mn), VANGUARD GROUP INC (11.38Mn), FMR LLC (8.92Mn), BlackRock, Inc. (7.36Mn), STATE STREET CORP (6.36Mn), PRICE T ROWE ASSOCIATES INC /MD/ (4.54Mn), GEODE CAPITAL MANAGEMENT, LLC (3.13Mn), MORGAN STANLEY (1.93Mn), Pictet Asset Management Holding SA (1.60Mn), APEIRON CAPITAL Ltd (1.31Mn).